Turn Therapeutics Inc. Diluted Shares Outstanding (Weighted Average)
Turn Therapeutics Inc. (TTRX) reported Diluted Shares Outstanding (Weighted Average) of 29.79 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-12
- Turn Therapeutics Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 29.79M shares, a 8.34% increase year-over-year.
- Turn Therapeutics Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 29.48M shares, a 9.35% increase year-over-year.
- Turn Therapeutics Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 28.43M shares, a 5.54% increase year-over-year.
- Turn Therapeutics Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 27.98M shares, a 4.99% increase year-over-year.
- Turn Therapeutics Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 27.72M shares, a 4.03% increase from fiscal 2024.
- Turn Therapeutics Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 26.64M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 29.79M shares 10-Q · filed 2026-08-12 | 29.63M shares 10-Q · filed 2026-08-12 | 29.23M shares derived: average of 3 quarters · filed 2026-08-12 | 28.92M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 29.48M shares 10-Q · filed 2026-05-11 | 28.95M shares derived: average of 2 quarters · filed 2026-05-11 | 28.63M shares derived: average of 3 quarters · filed 2026-05-11 | 28.34M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 28.43M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 28.20M shares derived: average of 2 quarters · filed 2026-03-31 | 27.97M shares derived: average of 3 quarters · filed 2026-08-12 | 27.72M shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 27.98M shares 10-Q · filed 2025-11-13 | 27.73M shares derived: average of 2 quarters · filed 2026-08-12 | 27.48M shares 10-Q · filed 2025-11-13 | 27.34M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 27.49M shares 10-Q · filed 2026-08-12 | 27.23M shares 10-Q · filed 2026-08-12 | 27.13M shares derived: average of 3 quarters · filed 2026-08-12 | 27.01M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 26.96M shares 10-Q · filed 2026-05-11 | 26.94M shares derived: average of 2 quarters · filed 2026-05-11 | 26.85M shares derived: average of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | 26.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 26.79M shares derived: average of 2 quarters · filed 2026-03-31 | 26.64M shares 10-K · filed 2026-03-31 | |
| 2024-09-30 | 26.65M shares 10-Q · filed 2025-11-13 | 26.55M shares 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |